The 21-valent pneumococcal conjugate vaccine V116 is well tolerated in adults living with HIV and induces immunity to all 21 ...

July 30, 2010 (Vienna, Austria) — Although initiation of highly active antiretroviral therapy (HAART) against HIV is associated with a lower risk for progression to AIDS, and a lower risk for ...

Doravirine/islatravir was noninferior to BIC/FTC/TAF and other ART in maintaining viral suppression, with minimal impact on CD4 and lymphocyte counts. Adverse events were similar between ...

An investigational once-weekly oral antiretroviral therapy (ART) combination effectively maintained viral suppression in adults with HIV-1 through 24 weeks, according to a phase IIb study. Among ...

Phase I study to evaluate the safety and efficacy of switchable CAR-T cell therapy with FY001 and CART001 in patients with refractory CD20-positive B-cell non-Hodgkin lymphoma (EPOC1803). CD4 ≥124.5 ...

What if the presence of a well-known but misunderstood viral protein explains why some people living with HIV (PLWH) never ...

Bluetoothing is a disturbing drug trend where users inject the blood of someone who is already high, hoping to feel the same effects. The practice has become one of the driving forces behind a ...

Hope for adults and children with cancers Camilla Jandus' team is currently preparing a clinical trial of TCR-engineered CD4-based cell therapy. The trial will include different types of cancer ...

Patritumab deruxtecan (HER3-DXd) in active brain metastases (BM) from metastatic breast (mBC) and non–small cell lung cancers (aNSCLC), and leptomeningeal disease (LMD) from advanced solid tumors: ...